Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $40.00 price target on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $33.00 to $38.00. They now have an "outperform" rating on the stock.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)